Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat

a technology of liver fat and progression inhibitor, which is applied in the direction of biocide, drug composition, metabolic disorder, etc., can solve the problems of lipid accumulation in liver, difficulty in controlling or continuing implementation of modalities, and incongruity of therapeutic modality

Inactive Publication Date: 2008-02-21
KISSEI PHARMA
View PDF1 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is believed that various factors including recent lifestyle changes overlap each other and abnormalities in liver energy metabolism are caused and as a consequence, lipid accumulation in liver occurs.
Therefore therapeutic modality is not uniform (see non-Patent Reference 5).
Although presently, dietary therapy, exercise therapy, pharmacotherapy and the like are tried as remedies for lipid accumulation in liver, these modalities have difficulties in control or continuing implementation.
Therefore, therapeutic effects are not always satisfied.
However, usefulness of diabetic drugs with blood glucose-lowering actions has been not confirmed, for example, it has been pointed out that tolbutamide does not exhibit suppressive effects on lipid accumulation in liver (see non-Patent Reference 7), and may adversely cause exacerbation of lipid accumulation in liver (see non-Patent Reference 6).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat

Examples

Experimental program
Comparison scheme
Effect test

example 1

Example 1

Test to Confirm Inhibitory Effect on Accumulation of Liver Lipids

[0024] Using KKAy mice (KKAy / Ta Jcl, CLEA Japan, Inc.) as experimental animals, inhibitory effects on accumulation of lipids in liver based on SGLT2 inhibitory effects were evaluated. KKAy mice bearing fatty liver were prepared as follows.

[0025] Female 10-week-old KKAy mice were bred preparatorily for 4 weeks. During preparatory breeding until 4 days before grouping, the mice were fed on a pellet CE-2 diet for laboratory animal (CLEA Japan, Inc.) under free feeding. From 4 days before grouping, the food was changed to a powdered CE-2 diet for laboratory animal (CLEA Japan, Inc.). At the age of 14 weeks, body weight, blood glucose level and plasma alanine aminotransferase level (ALT) were measured for grouping. The mice were grouped (5 animals in each group) so that in any of these three laboratory values no significant difference was observed between the two groups. In the second group, the mice were fed on ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
energy metabolismaaaaaaaaaa
weightaaaaaaaaaa
sizeaaaaaaaaaa
Login to view more

Abstract

The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcholic fatty liver disease (NAFL), non-alcholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcholic fatty liver disease toxic fatty liver or the like.

Description

TECHNICAL FIELD [0001] The present invention relates to an agent for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids, which comprises as an active ingredient a sodium / glucose co-transporter 2 (hereinafter referred to as SGLT2). BACKGROUND ART [0002] The patients with disorders in which lipids are abnormally accumulated in liver, such as non-alcoholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcoholic fatty liver, and toxic fatty liver as well as common fatty liver are increasing year by year. Above all, non-alcoholic steatohepatitis (NASH) is particularly acknowledged as a problem, because it exhibits serious symptoms (see non-Patent Reference 1 or 2). Moreover, it has been pointed out that abnormal lipid accumulation in liver causes liver inflammation or fibril formation in liver (liver cirrhosis) and makes shifts to serious disorders such as liver cancer (see non-Patent References 1 to 4), and thus, i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/7004A61P1/16
CPCA61K31/155A61K31/4427A61K31/7036A61K31/7028A61K31/57A61P1/16A61P3/00A61P3/04A61P3/06A61P3/10A61P35/00A61P43/00
Inventor KATSUNO, KENJIFUJIMORI, YOSHIKAZUISAJI, MASAYUKI
Owner KISSEI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap